This company has been marked as potentially delisted and may not be actively trading. NASDAQ:PNT POINT Biopharma Global (PNT) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About POINT Biopharma Global Stock (NASDAQ:PNT) Get POINT Biopharma Global alerts:Sign Up Key Stats Today's Range N/A50-Day Range$12.45▼$14.2352-Week Range N/AVolume3.29 million shsAverage Volume1.44 million shsMarket Capitalization$1.33 billionP/E Ratio13.89Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview POINT Biopharma Global Inc., a radiopharmaceutical company, develops and commercializes radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-alpha inhibitor targeting program being developed for use in various tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana. Read More Receive PNT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for POINT Biopharma Global and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PNT Stock News HeadlinesProta Therapeutics Strengthens Board with Appointment of Global Biotech Expert Patrick MachadoJuly 24, 2024 | markets.businessinsider.comWhat's Going On With GT Biopharma Stock?May 20, 2024 | msn.comNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $25 trillion AI revolution — one that Nvidia’s CEO himself has called a “multi-trillion-dollar future industry” — and he’s uncovered a little-known stock 168 times smaller than Nvidia that could be positioned to ride this breakthrough.October 22 at 2:00 AM | Brownstone Research (Ad)Investing in biopharma innovation: Can you stay one step ahead?April 8, 2024 | bloomberg.comDomain Therapeutics Strengthens Leadership Team to Spearhead Global Development and North American Expansion as the Leading GPCR Immuno-Oncology CompanyJanuary 8, 2024 | businesswire.comLilly Completes Acquisition of POINT BiopharmaDecember 27, 2023 | finance.yahoo.comPOINT Biopharma Global Rating Adjustment: Hold Recommendation Following Shareholder Dynamics and Acquisition ProspectsDecember 22, 2023 | markets.businessinsider.comBrookline Capital Downgrades POINT Biopharma Global (PNT)December 22, 2023 | msn.comSee More Headlines PNT Stock Analysis - Frequently Asked Questions How were POINT Biopharma Global's earnings last quarter? POINT Biopharma Global Inc. (NASDAQ:PNT) issued its quarterly earnings data on Monday, November, 13th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.07. The firm had revenue of $2.79 million for the quarter, compared to analyst estimates of $8 million. POINT Biopharma Global had a net margin of 39.62% and a trailing twelve-month return on equity of 21.10%. What other stocks do shareholders of POINT Biopharma Global own? Based on aggregate information from My MarketBeat watchlists, some other companies that POINT Biopharma Global investors own include NVIDIA (NVDA), Broadcom (AVGO), Novo Nordisk A/S (NVO), Disc Medicine (IRON), Arista Networks (ANET), e.l.f. Beauty (ELF) and Builders FirstSource (BLDR). Company Calendar Last Earnings11/13/2023Today10/22/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PNT CIK1811764 Webwww.pointbiopharma.com Phone64-7812-2417FaxN/AEmployees129Year FoundedN/AProfitability EPS (Trailing Twelve Months)$0.90 Trailing P/E Ratio13.89 Forward P/E RatioN/A P/E GrowthN/ANet Income$98.29 million Net Margins39.62% Pretax Margin52.16% Return on Equity21.10% Return on Assets18.28% Debt Debt-to-Equity Ratio0.01 Current Ratio9.14 Quick Ratio9.14 Sales & Book Value Annual Sales$226.58 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow13.31 Book Value$4.68 per share Price / BookN/AMiscellaneous Outstanding Shares106,570,000Free Float89,518,000Market Cap$1.33 billion OptionableOptionable BetaN/A A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for November 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:PNT) was last updated on 10/22/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredWhat Wall Street Won’t Say Out LoudDiscover the 7 key indicators before everyone else doesAmerican Alternative | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump cannot stop this trainThe Nobel Committee just confirmed what free-market thinkers have long argued — that true wealth isn’t built t...Porter & Company | SponsoredA Worldwide Gold Lockdown Is Now UnderwayCentral banks around the world are hoarding gold at one of the fastest rates in history — and former Goldman S...Stansberry Research | SponsoredElon Musk is on the lineElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredThe End of Elon Musk…?While headlines point to collapsing sales and fading tax credits, tech analyst Jeff Brown says Tesla is on the...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding POINT Biopharma Global Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share POINT Biopharma Global With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
